Capital Fund Management S.A. Takes $1.13 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Capital Fund Management S.A. acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 27,322 shares of the company's stock, valued at approximately $1,130,000. Capital Fund Management S.A. owned about 0.06% of Mirum Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Lord Abbett & CO. LLC acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $28,913,000. State Street Corp grew its position in Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company's stock valued at $69,955,000 after acquiring an additional 297,511 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $10,611,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Mirum Pharmaceuticals by 162.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company's stock worth $7,317,000 after purchasing an additional 109,585 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in shares of Mirum Pharmaceuticals by 15.8% in the fourth quarter. Loomis Sayles & Co. L P now owns 578,024 shares of the company's stock valued at $23,901,000 after purchasing an additional 78,708 shares during the period.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the sale, the senior vice president now directly owns 4,841 shares of the company's stock, valued at approximately $214,698.35. The trade was a 92.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Peter Radovich sold 3,177 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $152,241.84. Following the completion of the transaction, the chief operating officer now owns 29,588 shares in the company, valued at $1,417,856.96. The trade was a 9.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 116,473 shares of company stock worth $5,249,134 over the last ninety days. Company insiders own 22.87% of the company's stock.

Wall Street Analysts Forecast Growth

MIRM has been the topic of a number of analyst reports. HC Wainwright lifted their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $58.20.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock traded up $0.36 during midday trading on Monday, reaching $39.46. 18,968 shares of the stock traded hands, compared to its average volume of 521,780. The firm has a fifty day moving average price of $45.23 and a two-hundred day moving average price of $44.01. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $54.23. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -19.47 and a beta of 1.00. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $99.41 million during the quarter, compared to analysts' expectations of $96.64 million. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.